The rampant unauthorised and unproven stem cell transplant for spinal cord injury can leave a person paralysed below the level of injury, health experts said Thursday.
Issuing a statement to caution people about such practices and create awareness on the issue, the Association of Spine Surgeons of India (ASSI) said: "There is an urgent need to create awareness on the issue, and advise the spinal cord injured and their families to make informed decisions regarding the plethora of 'effective' stem transplant treatments being offered across the world."
"Over the past decade, various clinics in India and abroad have started offering experimental treatments, often involving transplants of stem cells, which are advertised as having beneficial effects, even though there is little or no evidence supporting such claims," said ASSI president Ram Chaddha.
He added these stem cells transplant procedures attempt to establish credibility by citing experimental studies that have no direct relation to the spinal cord injuries.
Sajan Hegde, consultant spine surgeon at Apollo Hospital who also heads its orthopaedics department, said the only accurate way to determine that a treatment is beneficial is to carry a properly designed study with an appropriate control group.
"It is important to conduct valid clinical trials to evaluate whether stem cell and cellular transplant can be offered as a valid option after the spinal cord injury. Some properly conducted trials are now being under taken, but it is advisable to wait for the results from these objective studies," he said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
